Comparison of an antimetabolic assay and an antiproliferative assay, both using 3H-Thymidine incorporation, to test drug sensitivity of human tumors

N. Zaffaroni, R. Silvestrini, E. Grignolio, R. Villa, C. DeMarco

Research output: Contribution to journalArticle

Abstract

Two assays based on the inhibition of 3H-thymidine incorporation into DNA were used to measure either the antimetabolic or the antiproliferative effects of anticancer drugs. A direct comparison of the two assays was made with cell suspensions obtained from 11 ovarian cancers and 22 malignant melanomas. Drugs with different effects on cell cycle phases were tested by both assays, for a total of 53 drug comparisons. When the sensitivity indices specific for each system was used, a significant association (p <0.001) was noted between the two assays. The agreement of both assays in defining in vitro sensitivity or resistance was 100% for ovarian cancer. For melanoma, 97% of samples resistant to the antimetabolic assay were also resistant to the antiproliferative assay; whereas, only 45% of samples sensitive to the antimetabolic assay were sensitive to the antiproliverative assay.

Original languageEnglish
Pages (from-to)392-403
Number of pages12
JournalInternational Journal of Cell Cloning
Volume6
Issue number6
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Cell Biology

Fingerprint Dive into the research topics of 'Comparison of an antimetabolic assay and an antiproliferative assay, both using 3H-Thymidine incorporation, to test drug sensitivity of human tumors'. Together they form a unique fingerprint.

  • Cite this